Abstract: In a method of preparing a liquid oat base a material comprising oat bran is suspended in an aqueous media and contacted with ?-amylase, ?-amylase, ?-glucanase, and xylanase to raise the concentration of soluble arabinoxylan by a factor of 5 or more. Also disclosed is a liquid oat base obtainable by the method; a powderous oat base obtained by drying the liquid oat base; uses of the liquid and powderous oat bases and food products comprising them. A powderous composition for use in preparing liquid oat base comprises oat bran, ?-amylase, ?-amylase, ?-glucanase, and xylanase.

Abstract: In a method of preparing a liquid oat base a material comprising oat bran is suspended in an aqueous media and contacted with ct-amylase, ?-amylase, ?-glucanase, and xylanase to raise the concentration of soluble arabinoxylan by a factor of 5 or more Also disclosed is a liquid oat base obtainable by the method; a powderous oat base obtained by drying the liquid oat base; uses of the liquid and powderous oat bases and food products comprising them. A powderous composition for use in preparing liquid oat base comprises oat bran, ct-amylase, ?-amylase, ?-glucanase, and xylanase.

Abstract: The present invention provides isolated full-length nucleic acid molecules encoding the novel PDE protein of the invention, and methods for uses thereof. The nucleic acid molecules of the invention also include peptide nucleic acids (PNA), and antisense molecules that react with the nucleic acid molecules of the invention. The invention also relates to agonists, antibodies, antagonists or inhibitors of the activity of novel PDE proteins. These compositions are useful for the diagnosis, prevention or treatment of conditions associated with the presence or the deficiency of novel PDE proteins.

Abstract: The present invention provides isolated full-length nucleic acid molecules encoding the novel PDE protein of the invention, and methods for uses thereof. The nucleic acid molecules of the invention also include peptide nucleic acids (PNA), and antisense molecules that react with the nucleic acid molecules of the invention. The invention also relates to agonists, antibodies, antagonists or inhibitors of the activity of novel PDE proteins. These compositions are useful for the diagnosis, prevention or treatment of conditions associated with the presence or the deficiency of novel PDE proteins.

Abstract: The present invention provides isolated full-length nucleic acid molecules encoding the novel PDE protein of the invention, and methods for uses thereof. The nucleic acid molecules of the invention also include peptide nucleic acids (PNA), and antisense molecules that react with the nucleic acid molecules of the invention. The invention also relates to agonists, antibodies, antagonists or inhibitors of the activity of novel PDE proteins. These compositions are useful for the diagnosis, prevention or treatment of conditions associated with the presence or the deficiency of novel PDE proteins.

Abstract: The present invention provides isolated full-length nucleic acid molecules encoding the novel PDE protein of the invention, and methods for uses thereof. The nucleic acid molecules of the invention also include peptide nucleic acids (PNA), and antisense molecules that react with the nucleic acid molecules of the invention. The invention also relates to agonists, antibodies, antagonists or inhibitors of the activity of novel PDE proteins. These compositions are useful for the diagnosis, prevention or treatment of conditions associated with the presence or the deficiency of novel PDE proteins.